Segment Information

9 Months Ended

Sep. 30, 2015

Segment Information

Segment Information

13. Segment Information

We currently operate as one operating segment. However, our chief operating decision makers regularly review revenues, cost of product sales and gross profit data as a primary measure of performance for each of our five commercial products.

Net revenues, cost of product sales and gross profit for each of our commercial products were as follows (in thousands):

	Three Months Ended September 30,
	Remodulin			Tyvaso		Adcirca		Orenitram		Unituxin			Total
2015
Net revenues	$	150,075		$	121,718	$	73,797	$	34,389	$	4,729		$	384,708
Cost of product sales	(2,242		)	3,517		4,555		2,084		(1,023		)	6,891
Gross profit	$	152,317		$	118,201	$	69,242	$	32,305	$	5,752		$	377,817
2014
Net revenues	$	142,877		$	119,685	$	51,247	$	14,460	$	—		$	328,269
Cost of product sales	16,915			16,878		3,087		3,923		—			40,803
Gross profit	$	125,962		$	102,807	$	48,160	$	10,537	$	—		$	287,466

	Nine Months Ended September 30,
	Remodulin		Tyvaso		Adcirca		Orenitram		Unituxin		Total
2015
Net revenues	$	432,313	$	350,939	$	187,248	$	81,145	$	4,729	$	1,056,374
Cost of product sales	7,105		15,936		11,242		7,556		1,888		43,727
Gross profit	$	425,208	$	335,003	$	176,006	$	73,589	$	2,841	$	1,012,647
2014
Net revenues	$	417,137	$	347,997	$	147,926	$	21,092	$	—	$	934,152
Cost of product sales	44,522		50,076		9,070		6,445		—		110,113
Gross profit	$	372,615	$	297,921	$	138,856	$	14,647	$	—	$	824,039

For the three-month periods ended September 30, 2015 and September 30, 2014, net revenues from our U.S.-based distributors represented 72 percent and 75 percent, respectively, of our total net operating revenues.

For each of the nine-month periods ended September 30, 2015 and September 30, 2014, net revenues from our U.S.-based distributors represented 74 percent and 75 percent, respectively, of our total net operating revenues.